Latest News in the pharma Industry

Research & Development

Champions Oncology collaborates with AstraZeneca to develop unique cohorts of PDX models

Champions Oncology collaborates with AstraZeneca to develop unique cohorts of PDX models

21 Aug 2017

Models will be used in AstraZeneca's oncology R&D programs in breast and lung cancer.

Read more 
BMS and Pfizer to highlight commitment to reducing the risk of stroke at ECS Congress 2017

BMS and Pfizer to highlight commitment to reducing the risk of stroke at ECS Congress 2017

20 Aug 2017

Eliquis clinical data include results from a Phase IV trial to be featured in late-breaking science sessions,

Read more 
A plant-based delivery system for anti-cancer drugs

A plant-based delivery system for anti-cancer drugs

20 Aug 2017

Study demonstrates that a complex consisting of tobacco mosaic virus and vcMMAE can kill cancer cells.

Read more 
Metacrine collaborates on development of FGF1 variants for glucose lowering and improving insulin sensitivity

Metacrine collaborates on development of FGF1 variants for glucose lowering and improving insulin sensitivity

16 Aug 2017

Novo Nordisk will have an option to license the FGF1 program upon achievement of certain research milestones.

Read more 
Regeneron to discontinue development of suptavumab for respiratory syncytial virus

Regeneron to discontinue development of suptavumab for respiratory syncytial virus

14 Aug 2017

Phase III study fails to meet its primary endpoint.

Read more 
Ionis to go it alone with Inotersen and IONIS-FB-L Rx after GSK decline

Ionis to go it alone with Inotersen and IONIS-FB-L Rx after GSK decline

14 Aug 2017

Inotersen on track for marketing authorization filings this year.

Read more 
Fortress Biotech forms new subsidiary, Aevitas Therapeutics

Fortress Biotech forms new subsidiary, Aevitas Therapeutics

14 Aug 2017

Subsidiary to develop novel AAV gene therapy treatments for complement-mediated.

Read more 
Kalytera submits Phase II study protocol to IRBs for cannabidiol in the prevention of GvHD

Kalytera submits Phase II study protocol to IRBs for cannabidiol in the prevention of GvHD

14 Aug 2017

The Phase II study is designed to generate the pharmacokinetic and safety data, at multiple dose levels, that will be required by the FDA.

Read more 
FDA removes clinical hold on CEL-SCI’s Phase III head & neck cancer trial

FDA removes clinical hold on CEL-SCI’s Phase III head & neck cancer trial

14 Aug 2017

The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

Read more 
Experimental treatment for Niemann-Pick disease type C1 appears safe, effective

Experimental treatment for Niemann-Pick disease type C1 appears safe, effective

13 Aug 2017

NIH-led clinical trial suggests that drug slows progression of rare neurological disease.

Read more 
Major progress in next generation medicines initiative

Major progress in next generation medicines initiative

10 Aug 2017

Juniper Pharma Services now has CrystecPharma’s supercritical fluid technology platform on-site.

Read more 
NCI study identifies essential genes for cancer immunotherapy

NCI study identifies essential genes for cancer immunotherapy

7 Aug 2017

This knowledge could speed the development of a new category of drugs.

Read more